Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.

Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y.

Cancer Res. 2010 Feb 15;70(4):1459-68. doi: 10.1158/0008-5472.CAN-09-3798. Epub 2010 Feb 2.


The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.

Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y.

Cancer Prev Res (Phila). 2010 Apr;3(4):539-48. doi: 10.1158/1940-6207.CAPR-09-0127. Epub 2010 Mar 16.


The role of polymorphisms in circadian pathway genes in breast tumorigenesis.

Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, Zhang W, Chen K.

Breast Cancer Res Treat. 2011 Jun;127(2):531-40. doi: 10.1007/s10549-010-1231-2. Epub 2010 Oct 27.


Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk.

Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y.

Mol Carcinog. 2012 Dec;51(12):923-9. doi: 10.1002/mc.20862. Epub 2011 Oct 17.


Breast cancer risk, nightwork, and circadian clock gene polymorphisms.

Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, Cordina-Duverger E, Sanchez M, Arveux P, Kerbrat P, Richardson S, Guénel P.

Endocr Relat Cancer. 2014 Aug;21(4):629-38. doi: 10.1530/ERC-14-0121. Epub 2014 Jun 11.


Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.

Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y.

Cancer Res. 2009 Apr 15;69(8):3605-13. doi: 10.1158/0008-5472.CAN-08-4572. Epub 2009 Mar 24.


microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.

Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y.

Cancer Res. 2009 Jul 15;69(14):5970-7. doi: 10.1158/0008-5472.CAN-09-0236. Epub 2009 Jun 30. Erratum in: Cancer Res. 2009 Aug 15;69(16):6758.


Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study.

Rabstein S, Harth V, Justenhoven C, Pesch B, Plöttner S, Heinze E, Lotz A, Baisch C, Schiffermann M, Brauch H, Hamann U, Ko Y, Brüning T; GENICA Consortium.

Chronobiol Int. 2014 Dec;31(10):1115-22. doi: 10.3109/07420528.2014.957301. Epub 2014 Sep 17.


[Association of genetic variantions of circadian clock genes and risk of breast cancer].

Wang WM, Yuan P, Wang JY, Ma F, Fan Y, Li Q, Zhang P, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):236-9. doi: 10.3760/cma.j.issn.0253-3766.2013.03.017. Chinese.


Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes.

Rossetti S, Esposito J, Corlazzoli F, Gregorski A, Sacchi N.

Cell Cycle. 2012 Jan 15;11(2):350-60. doi: 10.4161/cc.11.2.18792. Epub 2012 Jan 15.


Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.

Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y.

Cancer Lett. 2009 Nov 1;284(2):149-56. doi: 10.1016/j.canlet.2009.04.017. Epub 2009 May 19.


The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.

Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y.

Tumour Biol. 2015 May;36(5):3533-9. doi: 10.1007/s13277-014-2989-3. Epub 2015 Mar 5.


Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses.

Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y.

BMC Cancer. 2013 Oct 25;13:498. doi: 10.1186/1471-2407-13-498.


Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.

Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL.

Cancer Res. 2009 Dec 15;69(24):9315-22. doi: 10.1158/0008-5472.CAN-09-0648. Epub .


Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility.

Yu JC, Hsu HM, Chen ST, Hsu GC, Huang CS, Hou MF, Fu YP, Cheng TC, Wu PE, Shen CY.

J Biomed Sci. 2006 May;13(3):419-32. Epub 2006 Feb 25.


Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.

Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP.

Breast Cancer Res Treat. 2007 Oct;105(2):139-55. Epub 2007 Feb 13.


Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators, Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.


Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea.

Sung H, Lee KM, Choi JY, Han S, Lee JY, Li L, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D.

Breast Cancer Res Treat. 2011 Dec;130(3):939-51. doi: 10.1007/s10549-011-1656-2. Epub 2011 Jul 16.


Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers.

Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG.

Carcinogenesis. 2005 Jul;26(7):1241-6. Epub 2005 Mar 24.


Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies.

Taniguchi H, Fernández AF, Setién F, Ropero S, Ballestar E, Villanueva A, Yamamoto H, Imai K, Shinomura Y, Esteller M.

Cancer Res. 2009 Nov 1;69(21):8447-54. doi: 10.1158/0008-5472.CAN-09-0551. Epub 2009 Oct 27.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk